Skip to main content
Top

28-04-2024 | Bronchial Asthma | AIRWAY FIBROSIS

Neutralization of CX3CL1 Attenuates TGF-β-Induced Fibroblast Differentiation Through NF-κB Activation and Mitochondrial Dysfunction in Airway Fibrosis

Authors: Wun-Hao Cheng, Pao-Lung Chang, Yu-Chih Wu, Shao-An Wang, Chia-Ling Chen, Feng-Lin Hsu, Mei-May Neoh, Lee-Yuan Lin, Fara Silvia Yuliani, Chien-Huang Lin, Bing-Chang Chen

Published in: Lung

Login to get access

Abstract

Background

Severe asthma, characterized by inflammation and airway remodeling, involves fibroblast differentiation into myofibroblasts expressing α-SMA. This process leads to the production of fibronectin and connective tissue growth factor (CTGF), driven by factors such as transforming growth factor (TGF)-β. Furthermore, the persistent presence of myofibroblasts is associated with resistance to apoptosis and mitochondrial dysfunction. The chemokine (C-X3-C motif) ligand 1 (CX3CL1) plays a role in tissue fibrosis. However, it is currently unknown whether neutralization of CX3CL1 decreases TGF-β-induced fibroblast differentiation and mitochondrial dysfunction in normal human lung fibroblasts (NHLFs).

Methods

CX3CL1/C-X3-C motif chemokine receptor 1 (CX3CR1), CX3CL1 was analyzed by immunofluorescence (IF) or immunohistochemical (IHC) staining of ovalbumin-challenged mice. CX3CL1 release was detected by ELISA. TGF-β-induced CTGF, fibronectin, and α-SMA expression were evaluated in NHLFs following neutralization of CX3CL1 (TP213) treatment for the indicated times by Western blotting or IF staining. Mitochondrion function was detected by a JC-1 assay and seahorse assay. Cell apoptosis was observed by a terminal uridine nick-end labeling (TUNEL) assay.

Results

An increase in CX3CL1 expression was observed in lung tissues from mice with ovalbumin-induced asthma by IF staining. CX3CR1 was increased in the subepithelial layer of the airway by IHC staining. Moreover, CX3CR1 small interfering (si)RNA downregulated TGF-β-induced CTGF and fibronectin expression in NHLFs. CX3CL1 induced CTGF and fibronectin expression in NHLFs. TGF-β-induced CX3CL1 secretion from NHLFs. Furthermore, TP213 decreased TGF-β-induced CTGF, fibronectin, and α-SMA expression in NHLFs. Mitochondrion-related differentially expressed genes (DEGs) were examined after CX3CL1 neutralization in TGF-β-treated NHLFs. TP213 alleviated TGF-β-induced mitochondrial dysfunction and apoptosis resistance in NHLFs. CX3CL1 induced p65, IκBα, and IKKα phosphorylation in a time-dependent manner. Furthermore, CX3CL1-induced fibronectin expression and JC-1 monomer were decreased by p65 siRNA. TP213 reduced TGF-β-induced p65 and α-SMA expression in NHLFs.

Conclusions

These findings suggest that neutralizing CX3CL1 attenuates lung fibroblast activation and mitochondrial dysfunction. Understanding the impacts of CX3CL1 neutralization on fibroblast mitochondrial function could contribute to the development of therapeutic strategies for managing airway remodeling in severe asthma.
Literature
1.
go back to reference Vos T, Lim SS, Abbafati C et al (2020) Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 396:1204–1222CrossRef Vos T, Lim SS, Abbafati C et al (2020) Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 396:1204–1222CrossRef
2.
go back to reference Hough KP, Curtiss ML, Blain TJ et al (2020) Airway remodeling in asthma. Front Med 7:191CrossRef Hough KP, Curtiss ML, Blain TJ et al (2020) Airway remodeling in asthma. Front Med 7:191CrossRef
3.
go back to reference Hinz B, Lagares D (2020) Evasion of apoptosis by myofibroblasts: a hallmark of fibrotic diseases. Nat Rev Rheumatol 16:11–31CrossRefPubMed Hinz B, Lagares D (2020) Evasion of apoptosis by myofibroblasts: a hallmark of fibrotic diseases. Nat Rev Rheumatol 16:11–31CrossRefPubMed
4.
go back to reference Bueno M, Calyeca J, Rojas M, Mora AL (2020) Mitochondria dysfunction and metabolic reprogramming as drivers of idiopathic pulmonary fibrosis. Redox Biol 33:101509CrossRefPubMedPubMedCentral Bueno M, Calyeca J, Rojas M, Mora AL (2020) Mitochondria dysfunction and metabolic reprogramming as drivers of idiopathic pulmonary fibrosis. Redox Biol 33:101509CrossRefPubMedPubMedCentral
5.
6.
go back to reference Cormican S, Griffin MD (2021) Fractalkine (CX3CL1) and its receptor CX3CR1: a promising therapeutic target in chronic kidney disease? Front Immunol 12:664202CrossRefPubMedPubMedCentral Cormican S, Griffin MD (2021) Fractalkine (CX3CL1) and its receptor CX3CR1: a promising therapeutic target in chronic kidney disease? Front Immunol 12:664202CrossRefPubMedPubMedCentral
7.
go back to reference Zheng C, Xuan W, Chen Z et al (2022) CX3CL1 worsens cardiorenal dysfunction and serves as a therapeutic target of canagliflozin for cardiorenal syndrome. Front Pharmacol 13:848310CrossRefPubMedPubMedCentral Zheng C, Xuan W, Chen Z et al (2022) CX3CL1 worsens cardiorenal dysfunction and serves as a therapeutic target of canagliflozin for cardiorenal syndrome. Front Pharmacol 13:848310CrossRefPubMedPubMedCentral
8.
go back to reference Dong J, Ma Q (2019) In vivo activation and pro-fibrotic function of NF-κB in fibroblastic cells during pulmonary inflammation and fibrosis induced by carbon nanotubes. Front Pharmacol 10:1140CrossRefPubMedPubMedCentral Dong J, Ma Q (2019) In vivo activation and pro-fibrotic function of NF-κB in fibroblastic cells during pulmonary inflammation and fibrosis induced by carbon nanotubes. Front Pharmacol 10:1140CrossRefPubMedPubMedCentral
9.
go back to reference Wright JG, Christman JW (2003) The role of nuclear factor kappa B in the pathogenesis of pulmonary diseases: implications for therapy. Am J Respir Med 2:211–219CrossRefPubMed Wright JG, Christman JW (2003) The role of nuclear factor kappa B in the pathogenesis of pulmonary diseases: implications for therapy. Am J Respir Med 2:211–219CrossRefPubMed
10.
go back to reference Edwards MR, Bartlett NW, Clarke D et al (2009) Targeting the NF-κB pathway in asthma and chronic obstructive pulmonary disease. Pharmacol Ther 121:1–13CrossRefPubMed Edwards MR, Bartlett NW, Clarke D et al (2009) Targeting the NF-κB pathway in asthma and chronic obstructive pulmonary disease. Pharmacol Ther 121:1–13CrossRefPubMed
12.
go back to reference Reddy PH (2011) Mitochondrial dysfunction and oxidative stress in asthma: implications for mitochondria-targeted antioxidant therapeutics. Pharmaceuticals 4:429–456CrossRefPubMedPubMedCentral Reddy PH (2011) Mitochondrial dysfunction and oxidative stress in asthma: implications for mitochondria-targeted antioxidant therapeutics. Pharmaceuticals 4:429–456CrossRefPubMedPubMedCentral
14.
go back to reference Huang M, Nasab EM, Athari SS (2021) Immunoregulatory effect of mesenchymal stem cell via mitochondria signaling pathways in allergic asthma. Saudi J Biol Sci 28:6957–6962CrossRefPubMedPubMedCentral Huang M, Nasab EM, Athari SS (2021) Immunoregulatory effect of mesenchymal stem cell via mitochondria signaling pathways in allergic asthma. Saudi J Biol Sci 28:6957–6962CrossRefPubMedPubMedCentral
15.
17.
go back to reference Chen J-Y, Cheng W-H, Lee K-Y et al (2021) Abnormal ADAM17 expression causes airway fibrosis in chronic obstructive asthma. Biomed Pharmacother 140:111701CrossRefPubMed Chen J-Y, Cheng W-H, Lee K-Y et al (2021) Abnormal ADAM17 expression causes airway fibrosis in chronic obstructive asthma. Biomed Pharmacother 140:111701CrossRefPubMed
18.
go back to reference Cheng W-H, Lee K-Y, Yu M-C et al (2021) Pref-1 induced lung fibroblast differentiation by hypoxia through integrin α5β1/ERK/AP-1 cascade. Eur J Pharmacol 909:174385CrossRefPubMed Cheng W-H, Lee K-Y, Yu M-C et al (2021) Pref-1 induced lung fibroblast differentiation by hypoxia through integrin α5β1/ERK/AP-1 cascade. Eur J Pharmacol 909:174385CrossRefPubMed
19.
go back to reference Feng K, Meng P, Zou X et al (2022) IL-37 protects against airway remodeling by reversing bronchial epithelial–mesenchymal transition via IL-24 signaling pathway in chronic asthma. Respir Res 23:1–17CrossRef Feng K, Meng P, Zou X et al (2022) IL-37 protects against airway remodeling by reversing bronchial epithelial–mesenchymal transition via IL-24 signaling pathway in chronic asthma. Respir Res 23:1–17CrossRef
20.
go back to reference Mionnet C, Buatois V, Kanda A et al (2010) CX3CR1 is required for airway inflammation by promoting T helper cell survival and maintenance in inflamed lung. Nat Med 16:1305–1312CrossRefPubMed Mionnet C, Buatois V, Kanda A et al (2010) CX3CR1 is required for airway inflammation by promoting T helper cell survival and maintenance in inflamed lung. Nat Med 16:1305–1312CrossRefPubMed
21.
go back to reference Julia V (2012) CX3CL1 in allergic diseases: not just a chemotactic molecule. Allergy 67:1106–1110CrossRefPubMed Julia V (2012) CX3CL1 in allergic diseases: not just a chemotactic molecule. Allergy 67:1106–1110CrossRefPubMed
22.
go back to reference Rimaniol A-C, Till SJ, Garcia G et al (2003) The CX3C chemokine fractalkine in allergic asthma and rhinitis. J Allergy Clin Immunol 112:1139–1146CrossRefPubMed Rimaniol A-C, Till SJ, Garcia G et al (2003) The CX3C chemokine fractalkine in allergic asthma and rhinitis. J Allergy Clin Immunol 112:1139–1146CrossRefPubMed
23.
go back to reference Green G, Johnson SM, Costello H et al (2021) CX3CR1 is a receptor for human respiratory syncytial virus in cotton rats. J Virol 95:10–1128CrossRef Green G, Johnson SM, Costello H et al (2021) CX3CR1 is a receptor for human respiratory syncytial virus in cotton rats. J Virol 95:10–1128CrossRef
24.
go back to reference Cunoosamy D, Zhou X-H, Rehnberg M et al (2014) Expression of CX3CL1 and CX3CR1 in human asthmatic lung in relation to cell survival. Eur Respir J 44:3863 Cunoosamy D, Zhou X-H, Rehnberg M et al (2014) Expression of CX3CL1 and CX3CR1 in human asthmatic lung in relation to cell survival. Eur Respir J 44:3863
26.
27.
go back to reference Ishida Y, Kimura A, Nosaka M et al (2017) Essential involvement of the CX3CL1-CX3CR1 axis in bleomycin-induced pulmonary fibrosis via regulation of fibrocyte and M2 macrophage migration. Sci Rep 7:1–12CrossRef Ishida Y, Kimura A, Nosaka M et al (2017) Essential involvement of the CX3CL1-CX3CR1 axis in bleomycin-induced pulmonary fibrosis via regulation of fibrocyte and M2 macrophage migration. Sci Rep 7:1–12CrossRef
29.
go back to reference Sebag SC, Koval OM, Paschke JD et al (2017) Mitochondrial CaMKII inhibition in airway epithelium protects against allergic asthma. JCI Insight 2:e88297CrossRefPubMedPubMedCentral Sebag SC, Koval OM, Paschke JD et al (2017) Mitochondrial CaMKII inhibition in airway epithelium protects against allergic asthma. JCI Insight 2:e88297CrossRefPubMedPubMedCentral
30.
go back to reference Zhang Y, Do DC, Hu X et al (2021) CaMKII oxidation regulates cockroach allergen-induced mitophagy in asthma. J Allergy Clin Immunol 147:1464–1477CrossRefPubMed Zhang Y, Do DC, Hu X et al (2021) CaMKII oxidation regulates cockroach allergen-induced mitophagy in asthma. J Allergy Clin Immunol 147:1464–1477CrossRefPubMed
31.
go back to reference Susin SA, Lorenzo HK, Zamzami N et al (1999) Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 397:441–446CrossRefPubMed Susin SA, Lorenzo HK, Zamzami N et al (1999) Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 397:441–446CrossRefPubMed
32.
go back to reference Beere HM (2005) Death versus survival: functional interaction between the apoptotic and stress-inducible heat shock protein pathways. J Clin Investig 115:2633–2639CrossRefPubMedPubMedCentral Beere HM (2005) Death versus survival: functional interaction between the apoptotic and stress-inducible heat shock protein pathways. J Clin Investig 115:2633–2639CrossRefPubMedPubMedCentral
33.
go back to reference Drakopanagiotakis F, Xifteri A, Polychronopoulos V, Bouros D (2008) Apoptosis in lung injury and fibrosis. Eur Respir J 32:1631–1638CrossRefPubMed Drakopanagiotakis F, Xifteri A, Polychronopoulos V, Bouros D (2008) Apoptosis in lung injury and fibrosis. Eur Respir J 32:1631–1638CrossRefPubMed
35.
go back to reference Galán-Ganga M, García-Yagüe ÁJ, Lastres-Becker I (2019) Role of MSK1 in the induction of NF-κB by the chemokine CX3CL1 in microglial cells. Cell Mol Neurobiol 39:331–340CrossRefPubMed Galán-Ganga M, García-Yagüe ÁJ, Lastres-Becker I (2019) Role of MSK1 in the induction of NF-κB by the chemokine CX3CL1 in microglial cells. Cell Mol Neurobiol 39:331–340CrossRefPubMed
36.
go back to reference Mizutani S, Nishio J, Kondo K et al (2021) Treatment with an anti-Cx3cl1 antibody suppresses M1 macrophage infiltration in interstitial lung disease in Skg mice. Pharmaceuticals 14:474CrossRefPubMedPubMedCentral Mizutani S, Nishio J, Kondo K et al (2021) Treatment with an anti-Cx3cl1 antibody suppresses M1 macrophage infiltration in interstitial lung disease in Skg mice. Pharmaceuticals 14:474CrossRefPubMedPubMedCentral
Metadata
Title
Neutralization of CX3CL1 Attenuates TGF-β-Induced Fibroblast Differentiation Through NF-κB Activation and Mitochondrial Dysfunction in Airway Fibrosis
Authors
Wun-Hao Cheng
Pao-Lung Chang
Yu-Chih Wu
Shao-An Wang
Chia-Ling Chen
Feng-Lin Hsu
Mei-May Neoh
Lee-Yuan Lin
Fara Silvia Yuliani
Chien-Huang Lin
Bing-Chang Chen
Publication date
28-04-2024
Publisher
Springer US
Published in
Lung
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-024-00701-6
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.